CAS: 123-03-5; 1-Hexadecylpyridin-1-Ium Chloride

相似化合物

6004-24-6 104-74-5 6220-15-1

上下游产品

CAS号110-86-1 吡啶 | CAS号4860-03-1 氯代十六烷 | CAS号58527-29-0 Dichloro(hexade... | CAS号5392-40-5 柠檬醛 | CAS号24152-81-6 1-hexadecylpyri... | CAS号110-86-1 吡啶 | CAS号629-73-2 1-十六烯

4-(4-Dimethylamino-Phenylazo)-Benzenesulfonate1-Hexadecyl-Pyridinium;置于sodium Chloride体系中,化学反应生成氯化十六烷基吡啶,Methyl Orange
参考文献:甲基橙与亚胶束阳离子表面活性剂的相互作用
标题:甲基橙与亚胶束阳离子表面活性剂的相互作用
摘要:研发了水性甲基橙 (Mo)(一种偶氮染料)与亚胶束浓度范围内的烷基三甲基铵和 N-十六烷基吡啶鎓卤化物表面活性剂的相互作用.相互作用产生了一个新的 Mo 吸收带,最大值为约.370 Nm,新带的出现归因于水结构中发色团微环境的变化,使染料与亚胶束阳离子表面活性剂紧密堆积离子对.相互作用的强度取决于表面活性剂的烷基链长度,表面活性剂头基和反离子.
Doi:10.1246/bcsj.66.2457

专利信息

专利号:US-12383499-B2
优先权日:2018-01-01
标题:Scale up synthesis of silicasome nanocarriers
发明人：NEL ANDRE E; MENG HUAN; LIU XIANGSHENG
权利人:UNIV CALIFORNIA
摘要:In order to facilitate the approval and commercialization of silicasome drug delivery systems (e.g. irinotecan silicasomes) it is necessary to scale up synthesis of the drug-loaded silicasomes. In this regard, it was discovered that the synthesis protocols used for laboratory synthesis of drug-loaded silicasomes (e.g., 500 mg/batch) do not scale to large scale silicasome production, because the resulting products were too heterogeneous for use as pharmaceuticals. Accordingly, new methods are provided herein that effectively afford the large-scale production of mesoporous silica nanoparticles (MSNPs) and lipid bilayer coated MSNPs (silicasomes).

专利号:US-2008103312-A1
优先权日:2006-08-29
标 题:Processes for the synthesis of 5-phenyl-1-trityl-1H-tetrazole
发明人：KANSAL VINOD K; MISTRY DHIRENKUMAR N; VASOYA SANJAY L; LUNAGARIYA VIJAYKUMAR D
权利人:KANSAL VINOD K; MISTRY DHIRENKUMAR N; VASOYA SANJAY L; LUNAGARIYA VIJAYKUMAR D
摘要:Provided are processes for the synthesis of 5-phenyl-1-trityl-1H-tetrazole, an intermediate useful in the synthesis of irbesartan.

专利号:US-5595715-A
优先权日:1994-10-07
标 题:Synthesis of tetramethylammonium aluminosilicate and use thereof
发明人：ROTH WIESLAW J
权利人:MOBIL OIL CORP
摘要:There is provided a method for the preparation of tetramethylammonium aluminosilicate from tetramethylammonium hydroxide, a solid source of silica and a hydrolyzable aluminum compound. Tetramethylammonium aluminosilicate prepared by the above method is useful for the synthesis of M41S.

专利号:US-5300277-A
优先权日:1990-01-25
标题 :Synthesis of mesoporous crystalline material
发明人：KRESGE CHARLES T; ROTH WIELSAW J
权利人:MOBIL OIL CORP
摘要:This invention relates to an improvement in the method for synthesis of a new synthetic composition of porous crystalline material. The new crystalline material exhibits a large sorption capacity demonstrated by its benzene adsorption capacity of greater than about 10 grams benzene/100 grams at 50 torr and 25° C. and a particular, unique X-ray diffraction pattern.

专利号:US-2023323449-A1
优先权日:2021-12-17
标 题:Compositions and methods for detection of variants
发明人：GANTT RICHARD; ARNESON ADRIANA
权利人:TWIST BIOSCIENCE CORP
摘要:Testing the many hypotheses from genomics and systems biology experiments demands accurate and cost-effective gene and genome synthesis. Here we describe a microchip-based technology for multiplex gene synthesis. Pools of thousands of ‘construction’ oligonucleotides and tagged complementary ‘selection’ oligonucleotides are synthesized on photo-programmable microfluidic chips, released, amplified and selected by hybridization to reduce synthesis errors ninefold. A one-step polymerase assembly multiplexing reaction assembles these into multiple genes. This technology enabled us to synthesize all 21 genes that encode the proteins of the Escherichia coli 30S ribosomal subunit, and to optimize their translation efficiency in vitro through alteration of codon bias. This is a significant step towards the synthesis of ribosomes in vitro and should have utility for synthetic biology in general.

专利号:US-2002022022-A1
优先权日:2000-05-19
标题 :Inhibition of cell proliferation and matrix synthesis by antioxidants and NAD(P)H oxidase inhibitors
发明人：SHI YI; ZALEWSKI ANDREW
摘要:The present invention is directed to a method for the prophylactic and therapeutic treatment of diseases or disorders associated with the abnormal proliferation and extracellular matrix synthesis of smooth muscle cells (SMC) and fibroblasts due to activation of NAD(P)H and/or increased ROS generation. The method involves the administration of an NAD(P)H oxidase inhibitor(s) and/or antioxidant(s) to a mammal in an amount sufficient to treat the disease or disorder prophylactically or therapeutically. The NAD(P)H oxidase inhibitor inhibits the synthesis or translocation of NAD(P)H subunits, thereby blocking the generation of intracellular reactive oxygen species (ROS) and thus the proliferation and extracellular matrix synthesis of SMC and fibroblasts. Similarly, the administration of antioxidants blocks the generation of intracellular ROS, thereby inhibiting SMC and fibroblast proliferation and extracellular matrix synthesis. In addition to the prevention and treatment of vascular disease, such as atherosclerosis, graft disease, and restenosis, NAD(P)H oxidase inhibitors and antioxidants may be useful for the prevention and treatment of other conditions by decreasing cell proliferation and extracellular matrix synthesis associated therewith. These conditions include arthritis, keloid formation, cancer, tissue and organ fibrosis, and complications related to organ transplantation, metabolic syndrome, and radiation therapy.